SCHEMBL3565124

SCHEMBL3565124

CCCCOc1ccc(S(=O)(=O)Nc2cccc(CCc3ccccc3C(=O)O)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 2/20 0.49
CACNA1B Q00975 1/20 0.49
FABP1 P07148 1/20 0.49
MCL1 Q07820 1/20 0.49
BCL2A1 Q16548 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
METAP2 P50579 1/20 0.48
HTR6 P50406 4/20 0.47
GHSR Q92847 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SLC16A3 O15427 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565938 0.89 METAP2 (0.59) METAP2HTR6GHSRSLC16A3
SCHEMBL3561329 0.89 SMN1; SMN2 (0.58) WDR5SMN1; SMN2LMNAHTTCACNA1B
SCHEMBL3554315 0.88 WDR5 (0.64) WDR5SMN1; SMN2LMNAHTTCACNA1B
SCHEMBL3558965 0.88 CYP19A1 (0.57) HTTHTR6MEN1KMT2ASLC16A3
SCHEMBL3562892 0.87 METAP2 (0.57) METAP2HTR6GHSRSLC16A3
SCHEMBL3562226 0.86 ALDH1A1 (0.58) METAP2HTR6MEN1KMT2ASLC16A3
SCHEMBL3561338 0.85 HTR6 (0.62) MCL1BCL2A1METAP2HTR6SLC16A3
SCHEMBL3550679 0.85 WDR5 (0.57) WDR5SMN1; SMN2LMNAHTTCACNA1B
SCHEMBL3556527 0.85 ALDH1A1 (0.56) HTR6MEN1KMT2ASLC16A3
SCHEMBL3560029 0.84 WDR5 (0.59) WDR5SMN1; SMN2LMNAHTTCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 WDR5 1795/4885SMN1; SMN2 4522/4885LMNA 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.